Gain Therapeutics GANX 深 沪
等待开盘 08-26 09:30:00 美东时间
1.905
-0.095
-4.75%
华盛通- 最 高2.05
- 今 开2.00
- 成交量 38.34万股
- 最 低 1.90
- 昨 收 2.00
- 总市值 8314.11万
- 52周最高 4.34
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 1.53
- 委 比 81.39%
- 总股本 4364.36万
- 历史最高 17.93
- 量 比 1.18
- 振 幅 7.50%
- 历史最低 0.89
- 每 手 1
- 风险率 0.56%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gain Therapeutics Q2 EPS $(0.11) Beats $(0.14) Estimate
Gain Therapeutics (NASDAQ:GANX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 42.11 percent increase over losses of $(0.19) per share from the same period last year.
08-11 19:30
Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update
Gain Therapeutics provided an update on its lead drug candidate, rexaceract, for Parkinson’s disease. The Phase 1b study showed safety, tolerability, and early signs of efficacy, with reductions in biomarkers like GluSph and clinical benefits observed. The company received IND authorization and plans to start a Phase 2 study in Q3 2026. Additionally, a second candidate, GT-04686, is advancing in preclinical development. The company also announced...
07-16 11:00
美股大行评级 | 潜在涨幅392.61%！Chardan Capital维持EyePoint"买入"评级，上调目标价至65美元
今日重点评级关注：Chardan Capital：维持EyePoint"买入"评级，目标价从29美元升至65美元；康托·菲茨杰拉德：维持Hyperliquid Strategies"超配"评级，目标价从8美元升至18.4美元
07-02 18:41
HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $8 price target.
07-01 19:46
美股夜盘 | 707 Cayman Holdings涨62.04%，Abivax SA Sponsored ADR涨31.05%
GMEX ROBOTICS CORPORATION Class A涨-29.32%；Concentrix Corporation涨-22.83%；Decoy Therapeutics Inc.涨-16.37%
06-30 08:05
Gain Therapeutics advances GT-02287 into Phase 2 Parkinson’s trial
Gain Therapeutics ( ($GANX) ) has provided an announcement. On June 29, 2026, G...
06-30 04:51
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
Gain Therapeutics' GT-02287 has received FDA IND authorization, enabling Phase 2 clinical development in the U.S. for Parkinson's disease. Positive Phase 1 results showed target engagement, safety, and tolerability, with anecdotal improvements in symptoms. GT-02287, developed using Gain's Magellan AI platform, is the first allosteric modulator to achieve IND clearance. Phase 2 is expected to begin in 3Q26, involving sites in the U.S., Australia, ...
06-29 20:05
Gain Therapeutics (GANX) Receives a Buy from H.C. Wainwright
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy...
06-09 01:35
Gain Therapeutics Reports Interim Data for Parkinson’s Candidate
Gain Therapeutics ( ($GANX) ) has provided an update. On May 26, 2026, Gain The...
05-26 21:45
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Gain Therapeutics reported Q1 2026 financial results, highlighting increased R&D and G&A expenses due to GT-02287 development and currency fluctuations. The company presented promising Phase 1b data for GT-02287, showing biomarker improvements and stable MDS-UPDRS scores, supporting its disease-modifying potential for Parkinson's disease. GT-04686 also demonstrated activity in preclinical models. Upcoming milestones include IND clearance for GT-0...
05-11 11:00
